Literature DB >> 22906291

The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients.

L Yavuz1, G Aynali, A Aynali, A Alaca, S Kutuk, B G Ceylan.   

Abstract

OBJECTIVE: To determine the effect of immunoglobulin (Ig)M-enriched Ig therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome (MODS), using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score.
METHODS: Retrospective study of patients with sepsis-induced MODS treated with standard antibiotic plus supportive therapy (control group) or IgM-enriched Ig therapy adjuvant to control group therapy (IVIg group). Total length of stay in the intensive care unit (ICU), overall mortality rate and 28-day case fatality rate (CFR), as well as APACHE II scores and renal function parameters at day 1 and day 4 of therapy, were recorded.
RESULTS: A total of 118 patients were included (control group, n = 62; IVIg group, n = 56). In both groups, day 4 APACHE II scores decreased significantly compared with day 1 scores; the effect of treatment on renal function was minimal. Length of ICU stay, overall mortality rate and 28-day CFR were significantly lower in the IVIg group compared with the control group.
CONCLUSIONS: Adding IgM-enriched Ig therapy to standard therapy for MODS improved general clinical conditions and significantly reduced APACHE II scores, overall mortality rate and 28-day CFR, although effects on renal function were minimal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906291     DOI: 10.1177/147323001204000337

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  6 in total

Review 1.  Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.

Authors:  Christine S Cocanour; Phillip Chang; Jared M Huston; Charles A Adams; Jose J Diaz; Charles B Wessel; Bonnie A Falcione; Graciela M Bauza; Raquel A Forsythe; Matthew R Rosengart
Journal:  Surg Infect (Larchmt)       Date:  2017-04-04       Impact factor: 2.150

Review 2.  Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis.

Authors:  Axel Nierhaus; Giorgio Berlot; Detlef Kindgen-Milles; Eckhard Müller; Massimo Girardis
Journal:  Ann Intensive Care       Date:  2020-10-07       Impact factor: 6.925

Review 3.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

4.  Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study.

Authors:  Ildiko Toth; Andras Mikor; Tamas Leiner; Zsolt Molnar; Lajos Bogar; Tamas Szakmany
Journal:  J Anesth       Date:  2013-01-12       Impact factor: 2.078

5.  Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock.

Authors:  Ilaria Cavazzuti; Giulia Serafini; Stefano Busani; Laura Rinaldi; Emanuela Biagioni; Marta Buoncristiano; Massimo Girardis
Journal:  Intensive Care Med       Date:  2014-09-13       Impact factor: 17.440

6.  The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis.

Authors:  Jie Cui; Xuxia Wei; Haijin Lv; Yuntao Li; Ping Li; Zhen Chen; Genglong Liu
Journal:  Ann Intensive Care       Date:  2019-02-06       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.